Journal of Peking University(Health Sciences) >
Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma
Received date: 2021-01-11
Online published: 2021-08-25
Supported by
Scientific Research Seed Fund of Peking University First Hospital(2020SF36)
Objective: To investigate the clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma (FH-RCC). Methods: Immunohistochemical (IHC) staining was used to detect the expression of fumarate hydratase (FH) in tumor tissues of 109 different types of renal cell carcinoma (RCC) patients aged 60 years and younger from the Department of Urology of Peking University First Hospital from January 2013 to December 2019. The clinicopathological data and prognosis of FH-RCC were collected and analyzed. Results: There were eleven patients with FH-negative expression. Seven were males and four females. The age of onset ranged 16-53 years (mean age: 36.7 years), and four female patients all had a history of uterine leiomyoma. Only one first-degree relative of one patient had renal cancer, and none of the patients had a history or family history of cutaneous leiomyomas. The diameter of the tumor was 2.1-12.0 cm (mean: 8.83 cm). Renal sinus or perirenal fat invasion was seen in nine cases, tumor thrombus in renal vein or inferior vena cava in six cases, lymph node metastasis in seven cases, adrenal gland invasion in four cases and splenic capsule invasion in one case. The cases were initially diagnosed as type Ⅱ papillary RCC (7/49, 14.3%), collecting duct carcinoma (2/9, 22.2%) and unclassified RCC (2/51, 3.9%). Tumor histopathology mostly showed a mixture of different structures, such as papillary, tubular cystic, solid, and so on. The most common histological structures were papillary (9/11, 81.8%) and tubular (8/11, 72.7%). Three cases had sarcomatoid areas. At least focal eosinophilic nucleolus (WHO/grades Ⅲ-Ⅳ) and perinuclear halo could be seen in all cases. Immunohistochemical (IHC) stains of most tumors were negative for CA9, CD10 and CK7. The results of fluorescence in situ hybridization (FISH) showed that there was no translocation or amplification of TFE3 gene in two cases with TFE3 IHC expression. All the patients were followed up for 11-82 months. Mean survival was 24 months. Five cases died of distant metastasis 9-31 months after operation (mean: 19 months), and five of the six patients alive had became metastatic. Conclusion: Morphologically, FH-RCC overlaps with many types cell RCC. A mixture of papillary and tubular cystic arrangement is the most common growth pattern of FH-RCC. At least focally large and obvious eosinophilic nucleoli are an important histological feature of this tumor. The negative expression of FH can help to confirm the diagnosis. Young female RCC patients with uterine leiomyomas should be suspected of FH-RCC. Some FH-RCC cases lack clinical evidence. The suspicion raised by pathologists based on histological characteristics is often the key step to further genetic testing and the final diagnosis of the tumor.
Key words: Renal cell carcinoma; Fumarate hydratase; Immunohistochemistry; Prognosis
Yan-fei YU , Shi-ming HE , Yu-cai WU , Sheng-wei XIONG , Qi SHEN , Yan-yan LI , Feng YANG , Qun HE , Xue-song LI . Clinicopathological features and prognosis of fumarate hydratase deficient renal cell carcinoma[J]. Journal of Peking University(Health Sciences), 2021 , 53(4) : 640 -646 . DOI: 10.19723/j.issn.1671-167X.2021.04.003
| [1] | Pivovarcikova K, Martinek P, Grossmann P, et al. Fumarate hydratase deficient renal cell carcinoma: Chromosomal numerical aberration analysis of 12 cases [J]. Ann Diagn Pathol, 2019, 39:63-68. |
| [2] | 周婷婷, 邢金春. FH基因在遗传性平滑肌瘤病及肾癌综合征中的研究进展 [J]. 医学综述, 2014, 20(5):881-884. |
| [3] | Alam NA, Bevan S, Churchman M, et al. Localization of a gene (MCUL1) for multiple cutaneous leiomyomata and uterine fibroids to chromosome 1q42.3-q43 [J]. Am J Hum Genet, 2001, 68(5):1264-1269. |
| [4] | Tomlinson IP, Alam NA, Rowan AJ, et al. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer [J]. Nat Genet, 2002, 30(4):406-410. |
| [5] | Hansen AW, Chayed Z, Pallesen K, et al. Hereditary leiomyomatosis and renal cell cancer [J]. Acta Derm Venereol, 2020, 100(1): adv00012. |
| [6] | Chen YB, Brannon AR, Toubaji A, et al. Hereditary leiomyomatosis and renal cell carcinoma syndrome-associated renal cancer: Recognition of the syndrome by pathologic features and the utility of detecting aberrant succination by immunohistochemistry [J]. Am J Surg Pathol, 2014, 38(5):627-637. |
| [7] | Patel VM, Handler MZ, Schwartz RA, et al. Hereditary leiomyomatosis and renal cell cancer syndrome: An update and review [J]. J Am Acad Dermatol, 2017, 77(1):149-158. |
| [8] | Alam NA, Barclay E, Rowan AJ, et al. Clinical features of multiple cutaneous and uterine leiomyomatosis: An underdiagnosed tumor syndrome [J]. Arch Dermatol, 2005, 141(2):199-206. |
| [9] | Wei MH, Toure O, Glenn GM, et al. Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer [J]. J Med Genet, 2006, 43(1):18-27. |
| [10] | Menko FH, Maher ER, Schmidt LS, et al. Hereditary leiomyomatosis and renal cell cancer (HLRCC): Renal cancer risk, surveillance and treatment [J]. Fam Cancer, 2014, 13(4):637-644. |
| [11] | Ooi A. Advances in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) research [J]. Semin Cancer Biol, 2020, 61:158-166. |
| [12] | Alam NA, Rowan AJ, Wortham NC, et al. Genetic and functional analyses of FH mutations in multiple cutaneous and uterine leiomyomatosis, hereditary leiomyomatosis and renal cancer, and fumarate hydratase deficiency [J]. Hum Mol Genet, 2003, 12(11):1241-1252. |
| [13] | Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics [J]. Fam Cancer, 2011, 10(2):397-411. |
| [14] | Lau HD, Chan E, Fan AC, et al. A clinicopathologic and mole-cular analysis of fumarate hydratase-deficient renal cell carcinoma in 32 patients [J]. Am J Surg Pathol, 2020, 44(1):98-110. |
| [15] | Muller M, Ferlicot S, Guillaud-Bataille M, et al. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers [J]. Clin Genet, 2017, 92(6):606-615. |
| [16] | Alderson NL, Wang Y, Blatnik M, et al. S-(2-succinyl)cys-teine: A novel chemical modification of tissue proteins by a Krebs cycle intermediate [J]. Arch Biochem Biophys, 2006, 450(1):1-8. |
| [17] | Gupta S, Swanson AA, Chen Y, et al. Incidence of succinate dehydrogenase and fumarate hydratase-deficient renal cell carcinoma based on immunohistochemical screening with SDHA/SDHB and FH/2SC [J]. Hum Pathol, 2019, 91:114-122. |
| [18] | Trpkov K, Hes O, Agaimy A, et al. Fumarate hydratase-deficient renal cell carcinoma is strongly correlated with fumarate hydratase mutation and hereditary leiomyomatosis and renal cell carcinoma syndrome [J]. Am J Surg Pathol, 2016, 40(7):865-875. |
| [19] | Muller M, Guillaud-Bataille M, Salleron J, et al. Pattern multiplicity and fumarate hydratase (FH)/S-(2-succino)-cysteine (2SC) staining but not eosinophilic nucleoli with perinucleolar halos differentiate hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinomas from kidney tumors without FH gene alteration [J]. Mod Pathol, 2018, 31(6):974-983. |
| [20] | Wong MH, Tan CS, Lee SC, et al. Potential genetic anticipation in hereditary leiomyomatosis-renal cell cancer (HLRCC) [J]. Fam Cancer, 2014, 13(2):281-289. |
| [21] | Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fuma-rate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America [J]. Am J Hum Genet, 2003, 73(1):95-106. |
| [22] | Hol JA, Jongmans MCJ, Littooij AS, et al. Renal cell carcinoma in young FH mutation carriers: case series and review of the literature [J]. Fam Cancer, 2020, 19(1):55-63. |
| [23] | Merino MJ, Torres-Cabala C, Pinto P, et al. The morphologic spectrum of kidney tumors in hereditary leiomyomatosis and renal cell carcinoma (HLRCC) syndrome [J]. Am J Surg Pathol, 2007, 31(10):1578-1585. |
| [24] | Moch H, Cubilla AL, Humphrey PA, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs: part A: renal, penile, and testicular tumours [J]. Eur Urol, 2016, 70(1):93-105. |
| [25] | Ohe C, Smith SC, Sirohi D, et al. Reappraisal of morphologic differences between renal medullary carcinoma, collecting duct carcinoma, and fumarate hydratase-deficient renal cell carcinoma [J]. Am J Surg Pathol, 2018, 42(3):279-292. |
| [26] | Smith SC, Trpkov K, Chen YB, et al. Tubulocystic carcinoma of the kidney with poorly differentiated foci: A frequent morphologic pattern of fumarate hydratase-deficient renal cell carcinoma [J]. Am J Surg Pathol, 2016, 40(11):1457-1472. |
| [27] | Forde C, Lim D, Alwan Y, et al. Hereditary leiomyomatosis and renal cell cancer: Clinical, molecular, and screening features in a cohort of 185 affected individuals [J]. Eur Urol Oncol, 2020, 3(6):764-772. |
| [28] | Smith SC, Sirohi D, Ohe C, et al. A distinctive, low-grade oncocytic fumarate hydratase-deficient renal cell carcinoma, morpholo-gically reminiscent of succinate dehydrogenase-deficient renal cell carcinoma [J]. Histopathology, 2017, 71(1):42-52. |
| [29] | Launonen V, Vierimaa O, Kiuru M, et al. Inherited susceptibility to uterine leiomyomas and renal cell cancer [J]. Proc Natl Acad Sci USA, 2001, 98(6):3387-3392. |
| [30] | Choi Y, Keam B, Kim M, et al. Bevacizumab plus erlotinib combination therapy for advanced hereditary leiomyomatosis and renal cell carcinoma-associated renal cell carcinoma: A multicenter retrospective analysis in Korean patients [J]. Cancer Res Treat, 2019, 51(4):1549-1556. |
| [31] | Verine J, Pluvinage A, Bousquet G, et al. Hereditary renal cancer syndromes: An update of a systematic review [J]. Eur Urol, 2010, 58(5):701-710. |
| [32] | Joly D, Mejean A, Correas JM, et al. Progress in nephron sparing therapy for renal cell carcinoma and von Hippel-Lindau disease [J]. J Urol, 2011, 185(6):2056-2060. |
| [33] | Benson AB, Venook AP, Al-Hawary MM, et al. Rectal cancer, version 2. 2018, NCCN clinical practice guidelines in oncology [J]. J Natl Compr Canc Netw, 2018, 16(7):874-901. |
/
| 〈 |
|
〉 |